GlassScriptPhysician profile
Vivek Khetpal
NPI 1154394823
$5,788.10
in general payments reported to CMS, 2019-2025
46 companies · $384 in 2025
The $384 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,199 · 2020: $597 · 2021: $1,018 · 2022: $692 · 2023: $1,100 · 2024: $799 · 2025: $384.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,282.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $663.35 | 2022-2024 | |
| Abbott Laboratories | $433.22 | 2019-2025 | Aveir, Gallant, Jot Dx |
| Janssen Pharmaceuticals, INC | $427.36 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $307.87 | 2019-2025 | Ozempic, Wegovy |
| Pfizer INC. | $298.98 | 2020-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $288.23 | 2020-2025 | Lifevest |
| Merck Sharp & Dohme LLC | $245.43 | 2021-2023 | Verquvo, Steglatro, Belsomra |
| Astellas Pharma US INC | $236.99 | 2019 | |
| Sanofi-Aventis U.S. LLC | $232.41 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $229.18 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $204.11 | 2019-2021 | |
| Amgen INC. | $184.75 | 2021-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $146.88 | 2019-2024 | Resonate El Icd Vr |
| Heartflow, INC. | $134.69 | 2024 | |
| Indivior INC. | $134.54 | 2020-2023 | Sublocade |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $131.56 | 2023-2025 | Rexulti |
| Abiomed | $123.81 | 2022-2025 | |
| Ge Healthcare | $113.04 | 2021-2023 | |
| Impulse Dynamics (USA) INC. | $113.00 | 2023-2025 | Optimizer, Optimizer |
| Exact Sciences Corporation | $109.57 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Vivus LLC | $104.10 | 2023-2025 | Qsymia |
| Sunovion Pharmaceuticals INC. | $86.67 | 2019 | |
| Mylan Specialty L.P. | $77.81 | 2019-2021 | |
| Glaxosmithkline, LLC. | $70.01 | 2019-2023 | Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $68.98 | 2022-2024 | Camzyos |
| Inari Medical, INC. | $59.89 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Edwards Lifesciences Corporation | $55.88 | 2021-2023 | |
| Mannkind Corporation | $50.01 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $47.83 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $43.98 | 2020-2022 | |
| Irhythm Technologies, INC. | $43.93 | 2023 | Zio Xt Patch |
| Regeneron Healthcare Solutions, INC. | $43.81 | 2019 | |
| Bard Peripheral Vascular, INC. | $41.72 | 2020 | |
| Lilly USA, LLC | $34.62 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $31.50 | 2023-2024 | Inpefa |
| Cordis US Corp. | $19.34 | 2025 | Mynx Control |
| Biocryst Pharmaceuticals, INC. | $19.17 | 2020 | |
| Vital Connect, INC | $18.55 | 2025 | Vitalpatch Rtm |
| Avanir Pharmaceuticals, INC. | $17.36 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.81 | 2023 | |
| Philips North America LLC | $15.56 | 2022 | |
| Supernus Pharmaceuticals, INC. | $14.88 | 2020 | |
| Cardiovascular Systems INC. | $14.61 | 2020 | |
| Surmodics, INC. | $13.32 | 2023 | Pounce Thrombectomy, Sublime Radial Access Guide Sheath, Sublime 014 Rx Pta Balloon Dilatation Catheter |
| Takeda Pharmaceuticals U.S.A., INC. | $11.36 | 2021 | |
| Bardy Diagnostics, INC. | $8.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Vivek Khetpal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.